[1] Nakanishi T, Soyokura I, Toyokura Y, et al. Crow-Fukase syndrome:a study of 102 cases in japan. Neurology, 1984, 34:712-720. [2] Wang Q, Liu P, Ji LL, et al. Clinical and electrophysiological profiles in early recognition of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome. Chin Med J, 2019, 132: 1666-1672. [3] Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol, 2017, 92: 814-829. [4] Cui RT, Yu SY, Huang XS, et al. The characteristics of ascites in patients with POEMS syndrome. Ann Hematol, 2013, 92: 1661-1664. [5] 季丽莉, 王钦, 张雪皎, 等. 血清血管内皮生长因子在诊断POEMS综合征中的作用 (附2例报告). 中国临床神经科学, 2016, 24:288-293. [6] 朱卫国, 王玉, 曾学军, 等. POEMS综合征32例临床分析. 中华内科杂志, 2006, 45:108-111. [7] 李剑. POEMS综合征的诊断和治疗. 中国肿瘤临床, 2014, 29:1151-1154. [8] Jaccard A. POEMS syndrome: therapeutic options.Hematol. Oncol Clin North Am, 2018, 32: 141-151. [9] He H,Fu W,Du J, et al. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol, 2018, 181: 126-128. [10] 杨亚萍, 吴涛, 胡晓燕, 等. 硼替佐米治疗POEMS综合征一例. 中国医师进修杂志, 2017, 2: 182-183. [11] 刘延方, 周阳, 孙慧, 等. 含硼替佐米方案治疗 POEMS 综合征4例. 郑州大学学报: 医学版, 2016, 3: 426- 428. [12] 赵丹阳, 张弥兰, 冯淑曼, 等. POEMS综合征的临床特点及诊治分析.中国实用神经疾病杂志, 2017,20:82-83. |